Cargando…
A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus
BACKGROUND AND PURPOSE: In 2017, eculizumab has been approved for treatment-refractory generalised myasthenia gravis (TRgMG). The German Myasthenia Foundation has published a consensus statement on the use of eculizumab, with a recent update. However, a treatment-refractory state is still ill-define...
Autores principales: | Schroeter, Michael, Berger, Benjamin, Blaes, Franz, Hagenacker, Tim, Jander, Sebastian, Kaiser, Julia, Kalischewski, Petra, Lee, De-Hyung, Ruck, Tobias, Schara, Ulrike, Urban, Peter, Meisel, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863150/ https://www.ncbi.nlm.nih.gov/pubmed/33597816 http://dx.doi.org/10.1177/1179573521989151 |
Ejemplares similares
-
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
por: Stascheit, Frauke, et al.
Publicado: (2022) -
Understanding the burden of refractory myasthenia gravis
por: Schneider-Gold, Christiane, et al.
Publicado: (2019) -
Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022) -
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
por: Nelke, Christopher, et al.
Publicado: (2022) -
Fatigue in myasthenia gravis: risk factors and impact on quality of life
por: Hoffmann, Sarah, et al.
Publicado: (2016)